News

1 to 9 of 17 results

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Novartis' Ilaris gets new indication of childhood arthritis from US FDA

10-05-2013

Swiss pharmaceutical major Novartis (NIVN: VX) said this morning (May 10) that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsNorth AmericaPharmaceuticalRare diseasesRegulation

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

Pfizer's Elelyso approved in USA for Gaucher disease; Celebrex settlement

02-05-2012

The US Food and Drug Administration yesterday approved Elelyso (taliglucerase alfa) for injection, an…

Anti-Arthritics/RheumaticsCelebrexElelysoLegalNorth AmericaPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

27-04-2012

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

1 to 9 of 17 results

Back to top